NCT06746870 2024-12-24
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 2 Not yet recruiting